Hodgkin Lymphoma Program
Clinical trials
Dana-Farber Cancer Institute is a founding member of a small national consortium of leading medical centers that investigates new treatments for children with Hodgkin disease. Through this consortium, Dana-Farber/Children's Hospital Cancer Care (DF/CHCC) physicians are investigating new drug combinations that deliver better results with fewer long-term complications. Currently, we are accruing patients for a research studies investigating treatment for low-risk, intermediate risk and advanced Hodgkin disease.
In addition, DF/CHCC offers access to all Children's Oncology Group's Phase I clinical trials and other trials for relapsed Hodgkin.
